BioPharmSignal logoBioPharmSignal

Biotech News

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

Vaxcyte (PCVX)VaxcyteEarnings

Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Adult Phase 3 OPUS-1 Trial Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Phase 3 Results Expected in First Half of 2027 Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series and Booster Dose of

Related news

PCVXVaxcyte2026-05-06 20:05 EST

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-02-24 21:05 EST

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

VXRTVaxart2026-08-06 20:05 EST

Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results

VXRTVaxart2026-05-07 20:05 EST

Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results

GSKGSK plc2025-04-30 07:00 EST

GSK makes strong start to 2025 with growth in sales, profits and earnings

View all latest news

Vaxcyte

Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The...

Recent company news

PCVXVaxcyte2026-08-05 20:05 EST

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-07-08 20:05 EST

Vaxcyte to Participate in Upcoming Investor Conferences

PCVXVaxcyte2026-06-02 20:05 EST

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

PCVXVaxcyte2026-05-06 20:05 EST

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-04-07 20:05 EST

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

Stock data

Close
58.89 USD
Market cap
6.85B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States